Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- SARS-CoV-2 dataset
- Models of protective immunity – the basics (1)
- Models of protective immunity – the basics (2)
- To start: a textbook view of a typical, generic human immune response to viral infection (1)
- To start: a textbook view of a typical, generic human immune response to viral infection (2)
- To start: a textbook view of a typical, generic human immune response to viral infection (3)
- SARS-CoV-2 outcomes
- Important questions
- Many have tried to model the ‘Correlates of Protection’ - COP
- Neutralising antibodies as the key COP
- Neutralising antibody levels
- Keeping track of antibodies
- Differential SARS-CoV-2 response
- Antibody response (1)
- Antibody response (2)
- T cell response signature of patients who suffer severe or fatal infection
- Mapping CD4 and CD8 T cell responses (1)
- Mapping CD4 and CD8 T cell responses (2)
- Mapping CD4 and CD8 T cell responses (3)
- Mapping CD4 and CD8 T cell responses (4)
- T cell and nAb responses are variable & discordant
- Waning immunity (1)
- Waning immunity (2)
- Variants of concern, VOC (1)
- Variants of concern, VOC (2)
- Variants of concern, VOC (3)
- Vaccines, variants, reinfections & boosting
- Many difficult choices ahead
- The road ahead
- Future vaccination approaches
- Summary points
- Thank you for listening
Topics Covered
- COVID-19
- SARS-CoV-2
- Immunity
- T cells
- B cells
- Antibodies
- Adaptive immune response
- Innate immune response
- Variants of concern
- Correlates of protection
- CD4
- CD8
- Immunisation
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Altmann, D. (2022, July 25). COVID-19: the anti-viral immune response [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/KYKT9969.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Danny Altmann has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: The Immune System - Key Concepts and Questions
Transcript
Please wait while the transcript is being prepared...
0:00
Hello and welcome to
this talk on COVID-19:
the Anti-viral Immune Response.
I'm Danny Altmann.
I'm a professor of immunology
at Imperial College, London.
0:13
To start at the beginning.
For this talk, I'll
start quite basic
and build up to where we've
come to on the specifics
of the immune response
in the time of COVID.
If I date the dawn of
modern T cell and B cell
cellular immunology to
around 50 years ago,
since then immunologists
have learned
an enormous amount about
the nature of protective
immunity to some of the key
viruses that infect humans.
I guess we've accumulated
very large datasets
from studies looking at some of
the major pathogens
that have concerned us,
things like HIV, EBV,
CMV, flu, Hepatitis,
Dengue and even Zika.
But the coronavirus
family that we've
all become so obsessed with
in the last few years,
even including the common
cold coronaviruses
as well as SARS and MERS,
hadn't really been amongst the
most extensively
studied or understood.
But if you look at a little
graphic I've put here
of numbers of papers of content
published through 2019 to 2021,
you'll see that the
immunology of SARS-CoV-2,
the virus that causes COVID-19,
has become one of the
most massively studied
topics ever in human immunology.
1:32
Let's start at the
very beginning
and move on from there.
Obviously, when one learns
about protective immunity,
one tends to stratify it into
innate immunity and
adaptive immunity.
What do I mean by that?
Innate immunity refers to
intrinsic defence mechanisms
for recognising
microbial attack,
that something has
got into the body
from the environment
that shouldn't be there
and could be dangerous.
This includes everything from
the mucosal secretions
in the nasal pharynx,
but also white blood cells
such as neutrophils
and macrophages,
and the basic cellular responses
such as type 1 interferons.
These responses
are very rapid but
can be insufficient on their
own to prevent infection.
The key point is
they have no memory.
What do I mean by the
analogy of the word memory?
I mean that the
response will comprise
precisely the same features
and kinetics on the first,
second, or third encounter.
It doesn't get any
different or any better.
Also, the response isn't
particularly specific
to one virus
compared to another.